Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

St. Jude Medical, Inc. (STJ) Shares Rally Following Mistaken Report Of Acquisition Bid From Abbott Laboratories (ABT)

What does the smart money think about St. Jude Medical, Inc. (NYSE:STJ)?

Among the hedge funds that we track, Ivory Capital, led by Curtis Macnguyen, was the largest shareholder of St. Jude Medical, Inc. (NYSE:STJ), holding 1.61 million shares worth $117.31 million. David Stemerman of Conatus Capital Management was another major stakeholder of the company, with 1.38 million shares valued at $101.15 million. Ariel Investments and Balyasny Asset Management were among the other hedge funds owning a significant number of shares of the medical device manufacturer, 1.28 million and 646,326, respectively.

North Tide Capital, led by Conan Laughlin, initiated a new position in St. Jude Medical, Inc. during the second quarter, owning 500,000 shares with a market value of $36.54 million at the end of the quarter. Aaron Cowen of Suvretta Capital Management had 476,700 shares of the medical device maker in his portfolio. Gotham Asset Management and Millennium Management were among the hedge funds trimming their stakes in St. Jude Medical, Inc. (NYSE:STJ), ending the quarter with 72,464 and 172,002 shares respectively.

With positive hedge fund sentiment and strong second quarter financial results, St. Jude Medical, Inc. (NYSE:STJ) holds better prospects for the future, with or without a sale. We would recommend a long position in the company.

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
This is a FREE report from Insider Monkey. Credit Card is NOT required.